Pharmacology Sample Clauses

Pharmacology. Results of nonclinical pharmacology studies demonstrate the following: • FRα has limited normal tissue expression and marked expression in solid tumors, particularly cancers of the ovary and endometrium (Investigator Brochure). In vitro studies demonstrated that MIRV binds cell surface FRα with high apparent affinity (≤ 0.1 nM) and shows potent (IC50 ≤ 1 nM) and selective cytotoxicity against cells expressing FRα. MIRV-mediated cytotoxicity involves binding, internalization, and degradation of MIRV, which releases DM4. DM4 can be methylated to yield S- methyl-DM4. Both DM4 and S-methyl-DM4 can inhibit tubulin polymerization and microtubule assembly, causing cell death. The lipophilic molecules S-methyl DM4 and DM4 can also diffuse to neighboring cells and induce bystander killing. • In vitro cytotoxicity studies suggest that cells sensitive to MIRV express higher levels of FRα and release 10- to 100-fold more cytotoxic maytansinoid than cells resistant to MIRV. • MIRV retains the inherent activities of its Ab moiety, M9346A, including binding affinity (apparent affinity ≤ 0.1 nM) and selectivity for FRα, capacity for uptake, internalization and degradation by FRα-positive target cells, and ability to induce Ab- dependent cell-mediated cytotoxicity (ADCC) in vitro. • MIRV demonstrates significant activity against FRα-positive xenografts. Partial and/or complete regressions in xenograft models of EOC were seen at doses of MIRV well below its maximum tolerated dose (MTD).

Pharmacology. Sr No Name of Book Authors Edition Year Publisher Qty Reqd.

Pharmacology. Ciclosporin is thought to bind to the cytosolic protein cyclophilin (immunophilin) of immunocompetent lymphocytes, especially T-lymphocytes. This complex of ciclosporin and cyclophilin inhibits calcineurin, which, under normal circumstances, is responsible for activating the transcription of interleukin 2. It also inhibits lymphokine production and interleukin release and, therefore, leads to a reduced function of effector T-cells. Ciclosporin is an immunomodulator which acts upon T lymphoctes. Ciclosporin suppresses the immune system by preventing T lymphocytes from producing lymphokines. Lymphokines normally stimulate the growth of T and B lymphocytes, which are cells responsible for regulating and triggering immune responses. T cells are involved in producing inflammation as part of their immune function. Suppressing their action can help to reduce the inflammation in the joints of people who have rheumatoid arthritis or reduce inflammation in the skin of people who have cutaneous inflammatory conditions. Ciclosporin can promote a Th1 response in atopic dermatitis, altering IL-4 transcription and monocyte IL-10 production. Ciclosporin also has a direct effect on keratinocytes. 40% of an oral dose of ciclosporin is absorbed from the gut. Metabolism is hepatic and excretion is mostly in the bile with only 6% via urinary tract. • Prevention of organ rejection • Treatment of rheumatoid arthritis and psoriasis • Short term treatment of severe atopic dermatitis Non licensed dermatological indications include: Behcet’s disease, Chronic idiopathic urticaria, Connective tissue disease, immunobullous disease, Pyoderma gangrenosum, photodermatoses. Ciclosporin (oral solution or soft gelatin capsule) given twice a day based on patient’s weight, initially 2.5mg/kg/day. Available in 10mg, 25mg, 50mg or 100mg gelatin capsules or 100mg/ml solution. The solution can be mixed with fruit juice to improve the taste, but not grapefruit juice (this contains the flavinoid narigenin which inhibits CYP 3A4 activity and can increase plasma concentration of ciclosporin). Ciclosporin is given in divided doses from 2.5 to 4mg/kg/day in rheumatoid arthritis, and 2.5 to 5mg/kg/day in dermatology. • Tingling and numbness in the hands and feet: This usually subsides with time. • Trembling hands and feet and muscle cramps: Tonic water may help to alleviate any cramp pain. • Hypertrichosis: Increased growth of body hair can be removed by shaving, waxing or using a cream hair remover. A c...

Pharmacology. The aim of treatment is to reduce the production and absorption of ammonia in the gut. Current management of acute episodes of hepatic encephalopathy involves the use of antibiotics (such as neomycin) to inhibit ammonia- generating bacteria and disaccharides such as lactulose to convert soluble ammonia to insoluble ammonium. People with hepatic encephalopathy with low plasma ammonia may receive treatment with lactulose for the prevention of recurrence of acute episodes of hepatic encephalopathy. Rifaximin has a broad spectrum of activity against gram positive and gram negative, aerobic and anaerobic bacteria. In inhibiting the division of urea- deaminating bacteria, rifaximin decreases intestinal production and absorption of ammonia. It is administered orally and not systemically absorbed. The use of rifaximin has been demonstrated to reduce hospital admissions as a result of OHE and maintains remission in people with recurrent episodic OHE.3

Pharmacology. Tacrolimus is a macrolide immunosuppressant and is a calcineurin inhibitor. At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of lymphokine genes. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor. Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products. The formulations of Tacrolimus available include:  Prograf® normal release formulation - 0.5mg, 1mg and 5mg hard capsules.  Adoport® normal release formulation - 0.5mg, 1mg and 5mg hard capsules.  Capexion® normal release formulation - 0.5mg, 1mg and 5mg hard capsules.  Tacni® normal release formulation - 0.5mg, 1mg and 5mg hard capsules.  Vivadex® normal release formulation - 0.5mg, 1mg and 5mg hard capsules.  Advagraf modified release capsules - 0.5mg, 1mg and 5mg prolonged-release hard capsules (a minority of patients take the modified release capsules).  Envarsus® modified-release tablets -750 micrograms, 1mg, 4 mg  Modigraf® sugar-free granules – 0.2mg and 1mg It is imperative that tacrolimus is prescribed by brand name, in order to avoid confusion, due to the associated risk of either toxicity or rejection should the patient receive the wrong formulation. Different brands of Tacrolimus are not interchangeable.  Susceptibility to infections is increased in patients taking immunosuppressive therapy.  Risk of developing lymphomas and other malignancies, particularly of the skin, is increased in patients taking immunosuppressive therapy.  Haematological adverse effects also include anaemia, leukopenia, thrombocytopenia, leukocytosis, pancytopenia, and neutropenia.  Hypertension (adult renal patients BP >130/80mmHg) is a frequently encountered adverse effect. ∙Headache, tremor, insomnia and visual disorders ...

Pharmacology. BAB (OPG Farma, Utrecht, The Netherlands) was added to the extracellular solution from a stock of BAB in ethanol (1−500 mM). Final ethanol concentration never exceeded 0.1 %. Because BAB has low water solubility (<700 µM at room temperature, Merck Index 1989) and easily binds to plastic surfaces of the perfusion system, final BAB concentrations up to 500 µM were verified using absorption spectrophotometry (290 nm). m−Conotoxin−GVIA (CnTx; Peptide Institute Inc., Osaka, Japan) was dissolved in distilled water and added with a final fully blocking concentration of 3.3 or 5 µM (▇▇▇▇▇▇▇ et al., 1995; ▇▇▇▇▇▇▇ and ▇▇▇, 1992a; ▇▇▇▇▇ and ▇▇▇▇, 2002; ▇▇▇▇▇▇▇ and ▇▇▇, 1992b). Normalized data were corrected for rundown in the presence of vehicle (0.1 % ethanol) at all potentials measured in control experiments (n = 8). For example, at test pulses of 0 mV an apparent linear barium current decline (rundown) of ~ 6 % in 5 min was observed. The concentration−inhibition data were fitted using the Hill equation: I/Io = (1 + ([BAB]/IC50)n)−1, where the IC50 is the concentration at which the current is reduced by 50% and n is the Hill coefficient. Results are presented as mean ± standard deviation (M ± SD) for n cells, unless stated otherwise, and compared using paired or independent t−tests with the level of significance (p) chosen as 0.05.

Pharmacology. Methylphenidate, dexamfetamine and lisdexamfetamine (a pro-drug for dexamfetamine) are centrally-acting sympathomimetics. Their mechanism of action is mainly through inhibition of noradrenaline and dopamine transporters. Methylphenidate and lisdexamfetamine are the NICE treatments of first choice. Atomoxetine is a noradrenaline reuptake inhibitor which indirectly boosts dopamine. Drug prescribing in adults is usually off-label. Exceptions are atomoxetine, which is licensed for new treatment in adults with ADHD symptoms that can be confirmed from childhood, and lisdexamfetamine (as Elvanse Adult®) and Medikinet XL which is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Clinicians are supported in prescribing for adults with ADHD by the NICE NG 87, BAP (British Association of Psychopharmacology) guidelines. Three types of methylphenidate multiphasic XL preparations are available: • Concerta XL®, Matoride XL®, Xenidate XL® , Delmosart® or Xaggitin XL® tablets (22% Immediate Release [IR], 78% extended release [XL]) (See Appendix 1 for comparative costs of these once-daily methylphenidate products) • Equasym XL® capsules (30% IR, 70% XL) • Medikinet XL® capsules (50% IR, 50% XL) These different types of products are not interchangeable and the BNF recommends prescribing by brand name to avoid the risk of destabilisation from different release characteristics of the XL products dispensed generically. Strengths of Methylphenidate modified-release products: (22% Immediate Release [IR], 78% extended release [XL]) Concerta XL®: capsule-shaped tablets with internal hard membrane, 18mg (equivalent to 15mg of plain tablets), 27mg, 36mg or 54mg in packs of 28, or 30 Matoride XL®: cylindrical tablets with internal hard membrane, 18mg (equivalent to 15mg of plain tablets), 36mg or 54mg in packs of 28, 30, 60 or 90 Xenidate XL®: round, biconvex tablets, 18mg (equivalent to 15mg of plain tablets), 27mg, 36mg or 54mg in packs of 28, 30 or 100 Delmosart®: capsule-shaped, biconvex tablets, 18mg (equivalent to 15mg of plain tablets), 27mg, 36mg or 54mg in packs of 28, 30 or 90 Xaggitin XL®: capsule-shaped, biconvex tablets, 18mg (equivalent to 15mg of plain tablets), 27mg, 36mg or 54mg in packs of 28, 30 or 90 (See Appendix 1 for comparative costs of these methylphenidate products) Equasym XL®: (30% IR, 70% XL) capsules with small globules inside, 10mg, 20mg, 30mg in packs of 30 Medikinet XL®: (50% IR, 50%...

Pharmacology. Specific and reversible inhibitor of acetylcholinesterase Preparations available – 5mg and 10mg tablets and orodispersible tablets.

Pharmacology. Results of extensive pharmacodynamic evaluation demonstrating proof of concept in vivo for the immunotherapeutic construct selected for human health development. SAFETY EVALUATION Results of acute and subacute (less than or equal to 6 weeks) studies in two species, conducted to GLP, demonstrating the expected pharmacologically mediated effects on gonadal and associated organs (e.g. seminal vesicles; uterus) and the absence of non-mechanistic toxicity. CHEMISTRY AND PHARMACY Clinical trial supplies formulated and manufactured by a validated process and demonstrated to have biological potency in an in vivo batch release study. CLINICAL DEVELOPMENT CTX APPLICATION Documentation from above programme prepared in CTX format scheduled for submission in 3/4th week April 1996. CLINICAL TRIAL ORGANIZATION Protocol and associated documentation for initial proof of concept study in prostate cancer patients. Principal investigator identified. FORMULATION The process of Formulation of the Conjugate to facilitate the manufacture of Products.